January 23, 2019
Second Genome doses first patients in second phase testing SGM-1019
Second Genome has dosed first patient in a Phase 2 test of its oral, small molecule inhibitor of P2X7, called SGM-1019, for treating nonalcoholic steatohepatitis (NASH).